Beam Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation

Beam Therapeutics released its Q4 2025 earnings presentation, highlighting financial performance and operational milestones for the quarter ending December 31, 2025. The report underscores progress in its base-editing pipeline. The company emphasized advancements in its lead programs, including BEAM-101 for sickle cell disease and BEAM-201 for glycogen storage disease, with updated clinical trial timelines and safety data. Revenue growth was driven by partnerships, notably collaborations with Pfizer and Verve Therapeutics, though R&D expenses rose due to expanded clinical trials and platform development. Cash reserves and runway were detailed, with guidance suggesting sufficient funding to support operations into 2027, pending no major shifts in spending or market conditions. Executive commentary focused on strategic priorities for 2026, including regulatory submissions, new program initiations, and scaling manufacturing capabilities for gene-editing therapies.